Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 13, 2023

SELL
$191.51 - $216.16 $22 Million - $24.8 Million
-114,732 Reduced 36.94%
195,833 $41.5 Million
Q2 2023

Aug 11, 2023

SELL
$187.64 - $206.25 $192,143 - $211,200
-1,024 Reduced 0.33%
310,565 $59.8 Million
Q1 2023

May 15, 2023

SELL
$127.59 - $203.08 $2.58 Million - $4.1 Million
-20,195 Reduced 6.09%
311,589 $63.1 Million
Q4 2022

Feb 14, 2023

BUY
$117.37 - $139.17 $23.8 Million - $28.2 Million
202,685 Added 157.0%
331,784 $42.6 Million
Q3 2022

Nov 14, 2022

BUY
$135.27 - $180.11 $9.82 Million - $13.1 Million
72,616 Added 128.56%
129,099 $17.7 Million
Q2 2022

Aug 11, 2022

SELL
$108.81 - $179.33 $665,590 - $1.1 Million
-6,117 Reduced 9.77%
56,483 $10 Million
Q1 2022

May 16, 2022

SELL
$119.61 - $157.85 $7.09 Million - $9.36 Million
-59,285 Reduced 48.64%
62,600 $9.01 Million
Q4 2021

Feb 11, 2022

BUY
$142.57 - $190.86 $10.5 Million - $14 Million
73,609 Added 152.48%
121,885 $18.8 Million
Q3 2021

Nov 12, 2021

BUY
$142.45 - $169.82 $711,537 - $848,250
4,995 Added 11.54%
48,276 $8.15 Million
Q2 2021

Aug 13, 2021

BUY
$135.08 - $161.1 $1.38 Million - $1.65 Million
10,228 Added 30.94%
43,281 $6.83 Million
Q1 2021

May 14, 2021

BUY
$137.51 - $190.8 $317,098 - $439,984
2,306 Added 7.5%
33,053 $4.59 Million
Q4 2020

Feb 25, 2021

SELL
$164.63 - $211.93 $49,389 - $63,579
-300 Reduced 0.97%
30,747 $5.39 Million
Q4 2020

Feb 12, 2021

BUY
$164.63 - $211.93 $5.11 Million - $6.58 Million
31,047 New
31,047 $5.44 Million

Others Institutions Holding SGEN

About Seagen Inc.


  • Ticker SGEN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,664,992
  • Description
  • Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...
More about SGEN
Track This Portfolio

Track Hsbc Holdings PLC Portfolio

Follow Hsbc Holdings PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hsbc Holdings PLC, based on Form 13F filings with the SEC.

News

Stay updated on Hsbc Holdings PLC with notifications on news.